NanoBio Secures Novel Antigen Source for its Intranasal RSV Vaccine
ANN ARBOR - NanoBio Corporation announced a licensing agreement with the National Institutes of Health that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus infections. The agreement provides NanoBio with rights to a novel RSV antigen, developed by the NIH using proprietary viral-selection and reverse-genetics technology. RSV